uniQure (NASDAQ:QURE) Given New $14.00 Price Target at Royal Bank of Canada

uniQure (NASDAQ:QURE) had its price objective cut by Royal Bank of Canada from $16.00 to $14.00 in a report released on Wednesday morning, Benzinga reports. They currently have an outperform rating on the biotechnology company’s stock.

QURE has been the topic of a number of other research reports. HC Wainwright reiterated a “buy” rating and set a $25.00 target price on shares of uniQure in a report on Tuesday, August 20th. StockNews.com raised uniQure to a “sell” rating in a research note on Thursday, October 17th. Cantor Fitzgerald reissued an “overweight” rating and set a $28.00 price objective on shares of uniQure in a research report on Wednesday. The Goldman Sachs Group boosted their target price on shares of uniQure from $6.00 to $10.00 and gave the company a “neutral” rating in a report on Friday, August 2nd. Finally, Raymond James reiterated an “outperform” rating and issued a $20.00 price target on shares of uniQure in a research note on Thursday, October 10th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and four have issued a buy rating to the stock. Based on data from MarketBeat.com, uniQure has an average rating of “Hold” and an average price target of $17.00.

uniQure Trading Up 18.2 %

Shares of QURE opened at $7.16 on Wednesday. uniQure has a 1-year low of $3.73 and a 1-year high of $11.35. The company has a current ratio of 7.36, a quick ratio of 7.36 and a debt-to-equity ratio of 1.06. The firm’s 50-day moving average price is $5.70 and its 200-day moving average price is $5.79. The firm has a market capitalization of $348.69 million, a price-to-earnings ratio of -1.21 and a beta of 0.90.

Hedge Funds Weigh In On uniQure

A number of hedge funds have recently added to or reduced their stakes in the company. Vanguard Personalized Indexing Management LLC increased its holdings in shares of uniQure by 21.0% in the 2nd quarter. Vanguard Personalized Indexing Management LLC now owns 13,301 shares of the biotechnology company’s stock worth $59,000 after purchasing an additional 2,306 shares in the last quarter. China Universal Asset Management Co. Ltd. increased its holdings in uniQure by 57.0% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 10,093 shares of the biotechnology company’s stock worth $50,000 after buying an additional 3,663 shares in the last quarter. American Century Companies Inc. raised its position in uniQure by 14.6% in the 2nd quarter. American Century Companies Inc. now owns 67,699 shares of the biotechnology company’s stock worth $303,000 after buying an additional 8,642 shares during the last quarter. Atria Investments Inc bought a new position in uniQure during the 3rd quarter valued at about $53,000. Finally, Clear Harbor Asset Management LLC boosted its holdings in shares of uniQure by 35.2% during the 2nd quarter. Clear Harbor Asset Management LLC now owns 48,000 shares of the biotechnology company’s stock valued at $215,000 after acquiring an additional 12,500 shares during the last quarter. 78.83% of the stock is currently owned by hedge funds and other institutional investors.

uniQure Company Profile

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.